Aclaris Therapeutics, Inc. ACRS
We are a clinical-stage biopharmaceutical company focused on discovering and developing novel small and large molecule product candidates for immuno-inflammatory diseases. Our proprietary KINect drug discovery platform coupled with our integrated discovery approach to small and large molecules enables us to identify and advance product candidates designed to have superior target affinity, specificity and potency. We are seeking to identify and consummate transactions with third-party partners to further develop, obtain marketing approval for and/or commercialize our novel product candidates.
We are dedicated to developing a pipeline of novel product candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. Our approach to achieving this goal includes the following key elements:
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $7.8M | $18.7M | $31.2M | $29.8M | $6.8M | $6.5M | $4.2M | $6.2M | $1.7M | — |
| Cost of revenue | $2.1M | $2.8M | $3.4M | $4.0M | $4.7M | $5.1M | $4.1M | $4.3M | $1.2M | — |
| Gross profit | $5.7M | $15.9M | $27.8M | $25.7M | $2.0M | $1.3M | $172.0K | $3.2M | $476.0K | — |
| R&D | $52.6M | $33.6M | $98.4M | $77.8M | $43.8M | $29.3M | $64.2M | $60.8M | $35.8M | $33.5M |
| SG&A | $22.0M | $22.2M | $32.4M | $25.1M | $23.6M | $20.5M | $27.8M | $25.8M | $18.9M | $11.8M |
| Total operating expenses | $84.2M | $160.7M | $128.6M | $119.6M | $96.5M | $57.4M | $115.3M | $90.9M | $56.0M | $48.6M |
| Operating income | -$76.4M | -$141.9M | -$97.4M | -$89.9M | -$89.7M | -$50.9M | -$111.1M | -$84.8M | -$54.4M | -$48.6M |
| Pre-tax income | -$64.9M | -$132.1M | -$88.8M | -$86.9M | -$90.9M | -$51.3M | -$113.5M | -$82.1M | -$70.4M | -$48.1M |
| Income tax | — | — | $367.0K | — | — | $182.0K | — | — | $1.8M | — |
| Net income | -$64.9M | -$132.1M | -$88.5M | -$86.9M | -$90.9M | -$51.0M | -$161.4M | -$132.7M | -$68.5M | -$48.1M |
| EPS, basic | -0.53 | -1.71 | -1.27 | -1.33 | -1.60 | -1.20 | -3.90 | — | — | — |
| EPS, diluted | -0.53 | -1.71 | -1.27 | -1.33 | -1.60 | -1.20 | -3.90 | -4.03 | -2.44 | -2.25 |
| Shares, diluted (wtd. avg.) | 122.6M | 77.3M | 69.8M | 65.2M | 56.7M | 42.5M | 41.3M | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $20.0M | $24.6M | $39.9M | $45.3M | $27.3M | $22.1M | $35.9M | $57.0M | $20.2M | $30.2M |
| Short-term investments | $70.8M | $89.0M | $79.2M | $172.3M | $164.1M | $32.1M | $39.1M | $111.0M | $173.7M | $107.1M |
| Receivables | — | $318.0K | $298.0K | $484.0K | $623.0K | $772.0K | $704.0K | $563.0K | $481.0K | — |
| Inventory | — | — | — | — | — | — | $0 | $791.0K | — | — |
| Total current assets | $96.3M | $126.0M | $128.9M | $231.6M | $205.0M | $57.5M | $83.8M | $179.5M | $200.2M | $138.6M |
| Property, plant and equipment | $761.0K | $1.0M | $1.6M | $1.1M | $1.3M | $1.7M | $2.5M | $2.3M | $2.2M | $481.0K |
| Goodwill | — | — | — | — | — | — | — | $18.5M | $18.5M | — |
| Other intangibles | — | — | $269.0K | $7.0M | $7.0M | $7.1M | $7.2M | $7.3M | $7.3M | — |
| Total assets | $160.5M | $220.3M | $197.4M | $254.6M | $251.2M | $70.8M | $98.3M | $275.6M | $243.5M | $176.1M |
| Accounts payable | $13.2M | $4.7M | $8.9M | $10.4M | $10.0M | $5.3M | $9.9M | $11.7M | $7.8M | $2.8M |
| Total current liabilities | $28.6M | $31.6M | $31.0M | $21.9M | $22.9M | $14.9M | $22.4M | $27.3M | $12.8M | $6.2M |
| Long-term debt | — | — | — | — | — | $10.7M | — | $29.9M | — | — |
| Total liabilities | $57.4M | $64.8M | $40.2M | $57.0M | $53.9M | $33.1M | $28.4M | $60.4M | $18.2M | $6.6M |
| Retained earnings | -$967.8M | -$902.9M | -$770.8M | -$682.3M | -$595.4M | -$504.5M | -$453.5M | -$292.2M | -$159.4M | -$90.9M |
| Total equity | $103.1M | $155.6M | $157.2M | $197.6M | $197.3M | $37.6M | $69.9M | $215.1M | $225.3M | $169.5M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$47.1M | -$20.1M | -$78.3M | -$67.6M | -$52.1M | -$38.6M | -$96.4M | -$100.8M | -$54.7M | -$34.6M |
| Depreciation and amortisation | $454.0K | $807.0K | $863.0K | $797.0K | $923.0K | $1.3M | $6.4M | $1.9M | $402.0K | $120.0K |
| Stock-based compensation | $12.4M | $10.9M | $20.5M | $15.0M | $14.1M | $11.2M | $16.2M | $20.1M | $14.4M | $6.1M |
| Capital expenditure | $111.0K | $121.0K | $1.3M | $605.0K | $308.0K | $453.0K | $1.6M | $1.4M | $1.2M | $232.0K |
| Investing cash flow | $48.4M | -$69.8M | $46.2M | $12.6M | -$167.6M | $6.4M | $105.7M | $9.4M | -$55.7M | -$61.9M |
| Financing cash flow | -$5.9M | $74.5M | $26.7M | $72.9M | $225.1M | $18.4M | -$30.3M | $128.3M | $100.4M | $116.8M |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001104659-26-047262.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | $1.7M | $6.2M | $4.2M | $6.5M | $6.8M | $29.8M | $31.2M | $18.7M | $7.8M |
| Gross profit | — | $476.0K | $3.2M | $172.0K | $1.3M | $2.0M | $25.7M | $27.8M | $15.9M | $5.7M |
| Net income | -$48.1M | -$68.5M | -$132.7M | -$161.4M | -$51.0M | -$90.9M | -$86.9M | -$88.5M | -$132.1M | -$64.9M |
Recent filings and events
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Results announced Item 2.02
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Regulation FD disclosure Item 7.01
- Regulation FD disclosure Item 7.01
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Results announced Item 2.02
- Regulation FD disclosure Item 7.01
- Regulation FD disclosure Item 7.01
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.20T | 55.5x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $635.76B | 23.9x | 6.0% |
| ABBV | AbbVie Inc. | $504.76B | 121.0x | 8.6% |
| MRK | Merck & Co., Inc. | $358.41B | 20.0x | 1.3% |
| ABT | ABBOTT LABORATORIES | $180.63B | 27.9x | 5.7% |
| PFE | PFIZER INC | $171.16B | 22.1x | -1.6% |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $132.80B | 34.2x | 8.9% |
| BMY | BRISTOL MYERS SQUIBB CO | $125.59B | 17.8x | -0.2% |